MD Anderson wants to 'be part of the game,' partners with Radiopharm Theranostics for radioligand joint venture
The University of Texas MD Anderson Cancer Center has linked arms with Australian biotech Radiopharm Theranostics to build a joint venture dubbed Radiopharm Ventures.
The newly formed initiative will take four candidates from two MD Anderson scientists — David Piwnica-Worms and Samir Hanash — and push them through preclinical and Phase I studies over the course of the next three years. One of those candidates, a radioligand targeting the tumor antigen CD276, has already gone through preclinical studies, and the venture hopes to get it into its first clinical trial late next year, Radiopharm Theranostics CEO Riccardo Canevari told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
